Both facilities have been designed applying the highest standards in the field of gene and cell therapy in terms of plants, finishes, and laboratory instrumentation
Consolidated experience and successful track record in R&D and GMP production of retroviral and lentiviral vectors
Read moreTop level expertise in HSC and T-cells transduction services, from tech transfer to Drug Product filling and release
Read moreLocation: Frankfurt, Germany
MolMed at this event:
EURE-CART General Assembly
Dear Users, we would like to inform you that, as of 30 September, AGC Biologics S.p.A. (formerly MolMed S.p.A.) is no longer listed on the Milan Stock Exchange and has become part of the AGC Biologics Group. For any information on the company and the group, you are kindly invited to consult the websitewww.agcbio.com.
The contents present on this portal (www.molmed.com) are updated until the date of September 30, 2020 and will be available for the time frame foreseen by applicable regulations.
In addition, the "work with us" section is still active, while the contact details are no longer accessible.
